The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an
Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape
Researchers determine key protein structure that may lead to effective treatments for schizophrenia
Glycine is the smallest amino acid – one of the building blocks of proteins. It acts also as a neurotransmitter
Researchers reveal novel therapeutic target in the treatment of certain cancers
Mount Sinai Researchers Find "Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell
Researchers reveal novel therapeutic target in the treatment of certain cancers
Mount Sinai Researchers Find "Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell
Protein rewires metabolism to block cancer cell death, may allow cancer spread
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell
Protein rewires metabolism to block cancer cell death, may allow cancer spread
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell
New coronavirus variant with E484K mutation detected in Arizona
Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Researchers discover a gene mutation linked to schizophrenia
Researchers at The Feinstein Institutes for Medical Research, in collaboration with Columbia University, have identified a gene mutation that could
VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor
Co-founded back in 2014 by VHIO's Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of
SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion
A recent study by researchers in Switzerland found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding